Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.

被引：30

作者：

Borghaei, Hossein

Hellmann, Matthew David

Paz-Ares, Luis G.

Ramalingam, Suresh S.

Reck, Martin

O'Byrne, Kenneth John

Bhagavatheeswaran, Prabhu

Nathan, Faith Ellen

Brahmer, Julie R.

机构：

[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Hosp Univ Doce Octubre, Madrid, Spain

[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[5] LungenClin Grosshansdorf, German Ctr Lung Res, Grosshansdorf, Germany

[6] Princess Alexandra Hosp Brisbane, Queensland, Australia

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9001

引用

页数：2

Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with &lt;1% tumor PD-L1 expression: Results from CheckMate 227.